Urinary system neoplasm

This study tests a new medicine, PF-08634404, in adults with advanced bladder cancer that has spread. Some participants receive the drug alone, while others get it combined with another cancer drug. The goal is to check safety, how well it works, and how it affects the body. Abou…

This early-phase trial tests giving radiation therapy before surgery to people whose adrenal cancer has come back. The goal is to find a safe radiation dose and see if it helps shrink tumors before removal. About 32 adults with resectable recurrent ACC will receive daily radiatio…

This study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: fir…

This Phase 2 trial tests whether combining pembrolizumab (an immunotherapy) with aldesleukin (IL-2) can shrink tumors in people with advanced melanoma or kidney cancer that hasn't responded to prior treatments. About 78 adults will receive two cycles of the combo in the hospital,…

This early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This study tests whether adding a new targeted medicine (vepugratinib) to two standard cancer drugs can help people with advanced bladder cancer that has a specific genetic change (FGFR3). About 450 adults whose cancer has spread or cannot be removed by surgery will take part. Th…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

This early-stage trial is testing an investigational drug called GIM-122 in adults with advanced solid tumors that have not responded to standard treatments, including PD-1/PD-L1 inhibitors. GIM-122 is a special antibody designed to fight cancer in two ways. The study aims to fin…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This early-stage trial tests a new drug called PPM, which are tiny particles loaded with the chemotherapy drug paclitaxel and coated with a molecule (PLZ4) that helps them target bladder cancer cells. The drug is given directly into the bladder through a catheter once a week for …

This phase II trial tests whether adding precise, high-dose radiation (SABR) to the main kidney tumor improves outcomes for people with metastatic kidney cancer that cannot be surgically removed. Participants receive standard immunotherapy drugs (avelumab, axitinib, or cabozantin…

This early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…

This phase 2 trial tests whether a combination of enfortumab vedotin and pembrolizumab can help people with muscle-invasive bladder cancer avoid bladder removal. About 240 adults who are candidates for surgery will receive the drugs intravenously. The main goals are to see how ma…

This study tests a new drug called PF-08052667 for adults with a type of bladder cancer that hasn't spread into the muscle layer but is likely to return. The drug is given directly into the bladder, sometimes with other medicines like BCG or sasanlimab. The trial has three parts …

This study tests a new drug called YH42946 in people with advanced solid tumors that have certain gene changes (HER2 or EGFR). The main goals are to check safety and see if the drug shrinks tumors. About 161 adults who have run out of standard options will take part.

This study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…

This Phase 3 trial is testing whether adding the drug zanzalintinib to belzutifan helps people with advanced kidney cancer live longer and keep the cancer from growing. About 758 participants who have already tried standard treatments will receive either the combination or belzut…

This early-stage trial is testing a drug called orellanine, derived from a mushroom, in 75 people with advanced kidney cancer who are also on dialysis. The drug is given intravenously to see if it is safe and can shrink tumors. All participants have end-stage kidney disease and h…

This phase 2 study tests an investigational drug called telisotuzumab adizutecan in about 100 people aged 12 and older with advanced solid tumors that have a specific genetic change (MET amplification). The drug is given through an IV and aims to shrink tumors or stop them from g…

This study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …

This phase 3 trial is testing whether a combination of two drugs, SHR-A2102 and adebrelimab, works better than standard chemotherapy for people with advanced bladder cancer that has not been treated before. About 462 participants will be randomly assigned to receive either the ne…

This early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …

This early-stage study tests a new drug called 2141-V11 in people with a type of bladder cancer that hasn't responded to standard therapy. The drug is given directly into the bladder through a catheter or by injection into the tumor. The main goal is to see if it's safe and to fi…

This early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…

This phase 3 trial tests whether the experimental drug sacituzumab tirumotecan helps people with advanced bladder cancer live longer than standard chemotherapy. About 590 participants whose cancer worsened after prior treatments will receive either the new drug or one of several …

This early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…

This phase 2 trial is testing a combination of two drugs, enfortumab vedotin and pembrolizumab, in people with rare cancers of the bladder, urinary tract, or testicles. The study aims to see if these drugs can shrink tumors or slow disease progression. About 68 adults will receiv…

This phase II trial tests two drugs, lurbinectedin and avelumab, in people with a rare and aggressive bladder cancer called small cell carcinoma. Participants who have already had a drug like avelumab will receive only lurbinectedin; others will get both. The study aims to see if…

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…

This study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…

This phase 2 trial tests whether the drug sacituzumab govitecan, alone or combined with atezolizumab, can shrink rare tumors of the kidney, bladder, ureters, or penis. About 60 adults with specific rare cancer types will receive the drugs intravenously in 21-day cycles. The study…

This early-phase trial is testing whether giving the immunotherapy drug pembrolizumab (Keytruda) alone or with lenvatinib (Lenvima) before and after kidney cancer surgery can strengthen the immune system's attack on the tumor. About 30 adults with high-risk kidney cancer will rec…

This early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This phase 2 trial is testing whether giving chemotherapy before surgery to remove the bladder improves outcomes for people with a specific type of muscle-invasive bladder cancer called luminal subtype. Half the participants will receive standard neoadjuvant chemotherapy followed…

This phase III trial tests whether combining two drugs—pembrolizumab (an immunotherapy) and sacituzumab govitecan (a targeted chemotherapy)—works better than standard chemotherapy for people with advanced bladder cancer that has stopped responding to initial immunotherapy. About …

This study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…

This early-phase study tests a combination of two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. The main goal is to find safe doses and understand side effects. About 36 people will take part, and the study is currently re…

This Phase 2 trial tests the drug ivonescimab in 40 people with advanced clear cell renal cell carcinoma that has worsened after prior treatment. The goal is to see if the drug can help control the cancer and to monitor any side effects. Participants receive ivonescimab by IV inf…

This early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells carrying a specific marker (GPNMB). The study enrolls 30 adults in Canada with advanced alveolar soft part sar…

This early-stage trial tests a new drug called COM503, alone or with another drug zimberelimab, in 200 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is a first-in-human study, so effe…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.

This early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …

This study tests whether people with advanced kidney cancer can safely pause their medication after one year of treatment. Doctors will use a special PET scan that targets CD70 to decide who qualifies for a treatment break. The goal is to see if patients can stop drugs without th…

This study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…

This early-stage study tests a new drug, BMS-986506, in people with advanced clear cell kidney cancer that has not responded to prior treatments. The main goal is to check the drug's safety and how well the body tolerates it. About 125 participants will take the drug alone to see…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study tests a new combination of drugs (SHR-8068, adebrelimab, and others) in about 139 people with advanced kidney cancer that cannot be removed by surgery or has spread. The goal is to see if the treatment is safe and can shrink tumors. Participants will receive the drugs …

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This phase II trial compares two treatments for high-grade T1 bladder cancer that hasn't spread. One group gets the immunotherapy drug pembrolizumab plus radiation, while the other gets standard chemotherapy (cisplatin, gemcitabine, 5-fluorouracil, or mitomycin-C) plus radiation.…

This large trial is testing whether a blood test that looks for tumor DNA can help decide who needs immunotherapy after surgery for muscle-invasive urothelial cancer. About 992 participants will be assigned to different treatment plans based on their blood test results. The goal …

This phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …

This extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …

This study tests a drug called DS-8201a (trastuzumab deruxtecan) in children, teens, and young adults whose osteosarcoma, Wilms tumor, or desmoplastic small round cell tumor has come back or not responded to treatment. The drug works like a smart bomb, attaching to cancer cells a…

This early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…

This early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…

This trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This study tests whether using inhaled budesonide (a steroid commonly used for asthma) for one year can stop lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently had lung inflammat…

This study tests a new drug called EG-70 (detalimogene) for a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). The drug is given directly into the bladder through a catheter. The trial includes patients whose cancer did not respond to standard BCG therapy…

This early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…

This trial tests several cancer drugs in children and young adults with solid tumors. It uses a master protocol to test different drug combinations more efficiently. About 105 participants will receive one of eight drugs, including ramucirumab, cyclophosphamide, and others. The g…

This study tests whether giving belzutifan alone, pembrolizumab alone, or both together before kidney surgery can help control advanced clear cell kidney cancer. About 10 people with locally advanced disease will receive the drugs before partial or total kidney removal. The main …

This phase II trial tests whether adding the immunotherapy cemiplimab to the targeted drug cabozantinib works better than cabozantinib alone for advanced adrenocortical cancer. About 48 adolescents and adults whose cancer has spread or cannot be removed will take part. The study …

This phase 3 trial is testing a gene therapy called nadofaragene firadenovec, given directly into the bladder, either alone or combined with chemotherapy or immunotherapy. It is for people with a type of bladder cancer that has not responded to standard BCG therapy. The study aim…

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…

This early-phase trial tests whether adding radiation therapy or bladder removal surgery can safely eliminate remaining cancer in patients with advanced bladder cancer who have already responded to a drug combination. The study enrolls 12 adults with muscle-invasive bladder cance…

This phase 3 trial tests a gene therapy called nadofaragene firadenovec against simply watching and waiting in people with intermediate-risk non-muscle invasive bladder cancer. The study will enroll 454 participants who have had a tumor removed. The goal is to see if the gene the…

This Phase 2 trial tests an oral drug called TYRA-300 in 90 adults with a low-grade, intermediate-risk bladder cancer that has not invaded muscle. The cancer must have a specific genetic change (FGFR3 alteration). Participants take a daily tablet for up to 2 years. The main goal …

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This study tests whether two drugs, enfortumab vedotin and pembrolizumab, can control muscle-invasive bladder cancer without needing to remove the bladder. About 390 adults whose cancer hasn't spread outside the bladder will receive either the drug combo or standard chemoradiatio…

This early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…

This early-stage trial tests a new drug called JL19001, given alone or with standard BCG therapy, in 18 people with high-risk non-muscle invasive bladder cancer. The main goals are to check safety, find the right dose, and see how the body handles the drug. It's a first step to s…

This study is for people with muscle-invasive bladder cancer that has not spread. It tests whether removing only the part of the bladder with cancer (partial cystectomy) plus nearby lymph nodes works as well as removing the whole bladder. Participants get standard chemotherapy be…

This study tests three different drug combinations in 120 people with advanced kidney cancer that has spread. The goal is to see which combination works best to shrink tumors. Participants will receive either a new two-drug or three-drug combination, or a standard two-drug therap…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This early-phase trial is testing whether adding an experimental drug called emavusertib (CA-4948) to the immunotherapy pembrolizumab can help patients with advanced urothelial cancer whose tumors have become resistant to PD-1/PD-L1 blockers. The study will enroll 27 adults and f…

This early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…

This early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug throug…

This study tests a treatment plan for people with a rare, aggressive type of bladder cancer (variant histology) that has grown into the muscle layer. The goal is to see if giving chemotherapy (with or without immunotherapy) followed by radiation and low-dose chemo can save the bl…

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…

This trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…

This phase 3 trial tests whether adding the chemotherapy drug gemcitabine to standard BCG therapy can better prevent high-grade bladder cancer from coming back. About 330 people with recurrent non-muscle invasive bladder cancer will receive either BCG alone or BCG plus gemcitabin…

This early-stage trial tests a new drug, REGN15505, alone or with other drugs, in adults with advanced prostate or kidney cancer that has spread. The goal is to help the immune system attack cancer cells. About 265 participants will be enrolled to check safety, side effects, and …

This study tests whether adding tivozanib to the standard immunotherapy pembrolizumab works better than pembrolizumab alone to keep kidney cancer from returning after surgery. About 1040 adults with high-risk clear cell renal cell carcinoma will take part. The goal is to see if t…

This study tests a new drug called AVZO-103 in people with advanced bladder cancer or other solid tumors that have spread. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The trial will enroll about 355 adults and is the first time this drug i…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…

This study tests a drug called ivonescimab given before surgery for high-risk kidney cancer that hasn't spread. The drug helps the immune system attack cancer and may also block blood vessel growth to tumors. About 31 people with clear cell kidney cancer will receive the drug bef…

This trial tests two different drug combinations given directly into the bladder for people with a type of bladder cancer that has not responded to the standard BCG therapy. Participants are randomly assigned to receive either gemcitabine plus docetaxel or gemcitabine plus mitomy…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This phase 2 trial tests two drugs, enfortumab vedotin and pembrolizumab, in 47 people with muscle-invasive bladder cancer. The goal is to see if the combination can eliminate the cancer so patients can keep their bladder instead of having it surgically removed. After three cycle…

This trial investigates whether tumor-infiltrating lymphocytes (TILs) — immune cells taken from a patient's own tumor — can be expanded in the lab and infused back to attack cancer. It enrolls adults aged 18 to 75 with advanced solid tumors who have failed standard treatments. Th…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder cancer surgery is safe and effective. About 150 people with muscle-invasive bladder cancer will receive durvalumab plus either ddMVAC or gemcitabine/cisplatin chemo…

This study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …

This early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before surgery helps shrink tumors in people with high-grade upper urinary tract cancer. About 131 adults will be randomly assigned to receive either chemo alone or chemo plus durvalumab be…

This study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…

This early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…

This phase II trial is testing whether combining precise, high-dose radiation (SABR) with the targeted drug axitinib and the immunotherapy toripalimab can shrink or control tumors in people with oligometastatic clear cell renal cell carcinoma—kidney cancer that has spread to five…

This early-stage study tests a new drug called XmAb819 in people with advanced clear cell kidney cancer that has come back or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 307 participants will receive the drug int…

This study tests a new drug called dabogratinib in 230 adults with a rare, low-grade cancer in the upper part of the urinary tract. The goal is to see if the drug can make the cancer disappear completely within 6 months. Participants take the drug by mouth and are monitored for s…

This early-stage study tests a new drug called NEO-811 in people with advanced clear cell kidney cancer that has spread or cannot be surgically removed. The goal is to find the safest dose and see how well the drug works. About 30 participants who have already tried other treatme…

This study tests whether altering gut bacteria can restore the effectiveness of immunotherapy in people with advanced kidney cancer. About 33 adults will receive a bowel cleanse, a live bacterial supplement, and then a combination of immunotherapy drugs. The goal is to see if thi…

This study tests whether a combination of two oral drugs, belzutifan and zanzalintinib, works better than the current standard drug cabozantinib for people with advanced kidney cancer that has come back after prior treatment. About 904 participants will be randomly assigned to on…

This trial is investigating whether giving a combination of gemcitabine and trastuzumab rezetecan before surgery can improve outcomes for people with HER2-positive upper tract urothelial carcinoma, a rare cancer of the kidney's drainage system. Participants will receive four cycl…

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…

This early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …

This study tests a gel form of the chemotherapy drug gemcitabine, called ST-02, for people with low-grade cancer in the upper urinary tract. The gel is placed directly into the kidney through a small tube. The goal is to see if it can destroy tumors within three months and remain…

This early-stage trial is testing an experimental oral drug called OATD-02 in people with advanced or metastatic colorectal, ovarian, pancreatic, or renal cell cancer. The goal is to see if the drug is safe and whether it can help the immune system attack tumors by increasing arg…

This study tests a new drug called LM-168 combined with other cancer treatments (tislelizumab or docetaxel) in 108 adults with advanced solid tumors. The first part finds a safe dose; the second part checks if the combination shrinks tumors. It is not yet recruiting.

This early-phase trial is testing whether adding sitagliptin, a diabetes drug, to the immunotherapy pembrolizumab is safe and can help people with advanced kidney cancer or melanoma whose cancer has stopped responding to standard treatment. The study will first find the safest do…

This study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 par…

This early-phase trial is testing a new treatment called LNK001 for people with advanced or metastatic clear cell renal cell carcinoma (a type of kidney cancer) that has not responded to standard treatments. LNK001 is a type of immunotherapy where a patient's own immune cells are…

This early-phase study tests an experimental drug called ZE94-0605 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for any signs of tumor shrinkage. The study is not yet recruiting.

This trial tests whether an oral herbal supplement called LCS103 can help prevent non-muscle invasive bladder cancer from recurring after surgery. Sixty adults who have had their bladder tumors completely removed will take either LCS103 plus standard care or standard care alone f…

This phase II trial is testing whether combining enfortumab vedotin—a drug that delivers a cancer-killing agent directly to tumor cells—with the immunotherapy pembrolizumab can shrink tumors in people with locally advanced or metastatic bladder cancer of variant histology. These …

This early-phase trial is testing an experimental drug called ROSE12, alone or combined with other anti-tumor agents, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to evaluate safety, determine the best dose, and look…

This early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatme…

This Phase 2 trial is testing two experimental drugs (SSGJ-705 and SSGJ-612) with or without chemotherapy in 150 adults with advanced HER2-positive solid tumors, including colorectal, bladder, breast, bile duct, and stomach cancers. The goal is to see if the combination can shrin…

This early-stage trial tests an experimental drug called E303 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goals are to check safety and see if the …

This phase 3 trial is testing an experimental drug called VC004 in people aged 12 and older with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see whether VC004 capsules can shrink tumors and control the disease. All participants receive th…

This large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…

This phase 2 trial tests a new drug called zanzalintinib, taken as a pill, combined with a bone-strengthening agent for people with advanced kidney cancer that has spread to the bones. The study enrolls 20 participants whose cancer has worsened after 1–3 prior treatments, includi…

This study explores whether adding high-intensity interval training (HIIT) to standard immunotherapy (nivolumab plus ipilimumab) helps patients with advanced kidney cancer. Thirty participants are randomly assigned to either a supervised exercise program or usual care. Researcher…

This early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body proces…

This early-phase trial is testing an experimental drug called M3T01, a monoclonal antibody that targets a protein called FasL, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to see if M3T01 is safe and tolerable when given al…

This phase II trial is testing whether combining an experimental drug called BL-B01D1 with a PD-1 inhibitor can shrink tumors in people with advanced or metastatic urothelial carcinoma (a type of bladder cancer) who have not had prior systemic therapy. The study will measure how …

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This trial is testing an experimental drug called AT-1965 in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and then seeing whether the drug can shrink tumors. About 100 participants will…

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This phase 3 trial is testing whether a combination of two drugs—datopotamab deruxtecan and rilvegostomig—given after surgery can prevent cancer recurrence in people with high-risk muscle invasive bladder cancer. Participants who have had their tumor completely removed will recei…

This phase 2 trial tests whether adding one of four different drugs to a standard immunotherapy combination can help people with HER2-positive muscle-invasive bladder cancer avoid bladder removal. Participants receive disitamab vedotin and toripalimab plus a sensitizing agent, th…

This early-stage trial tests an experimental oral drug called APG-2449, alone or combined with another cancer drug, in people with platinum-resistant recurrent ovarian cancer or other advanced solid tumors. The study aims to find safe doses and understand how the drug works in th…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This trial tests whether giving two drugs—enfortumab vedotin and pembrolizumab—before surgery can improve outcomes for people with upper tract urothelial cancer (a type of bladder cancer in the kidney or ureter). Participants receive the drugs intravenously, then undergo surgery …

This phase 1 trial tests an experimental drug called ACM-CpG, given as a shot into the muscle, in people with advanced solid tumors that have not responded to standard immunotherapy. The drug is designed to activate the immune system to attack tumors. The study aims to find the s…

This phase 1 trial tests an experimental drug called PA5 in adults with advanced solid tumors that have not responded to standard treatments. PA5 is designed to break down arginine, an amino acid some cancers need to grow. The study aims to find the safest dose and check for side…

This study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…

This early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…

This clinical trial is testing whether a combination of two drugs, SHR-A2102 and adebrelimab, works better than standard chemotherapy for people with muscle-invasive bladder cancer. The treatment is given before and after surgery to remove the bladder. The study involves 840 part…

This study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…

This study tests a new drug called ICP-B208 in about 539 people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. Participants must be 18-75, have failed pr…

This phase 3 trial tests whether combining the targeted drug disitamab vedotin (RC48) with chemotherapy (gemcitabine) before surgery works as well as RC48 plus an immunotherapy (toripalimab) for people with HER2-positive muscle-invasive bladder cancer. Participants receive one of…

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This study tests a program where clinical pharmacists provide personalized counseling to cancer patients taking oral anticancer drugs. The goal is to see if this support helps patients take their medication more consistently. Researchers will compare two groups of 80 patients eac…

This trial tests a two-part approach for advanced clear cell kidney cancer that has stopped responding to standard treatments. First, an imaging injection (PD-32766D) lights up cancer cells that have a specific marker (CA9). If the scan shows the marker is present, participants t…

This study tests a combination of two treatments for people with localized clear cell kidney cancer that can be surgically removed. The first is a personalized vaccine made from the patient's own immune cells, designed to target proteins found on tumor blood vessels. The second i…

This early-stage study tests a chemotherapy drug (JNJ-1761981) that is injected directly into tumors in people with solid cancers that have not responded to standard treatments. The goal is to find a safe and effective dose, and to see if adding an immunotherapy (cetrelimab) help…

This study tests whether adding an experimental cell therapy called IBR854 to the standard drug pazopanib works better than pazopanib alone for advanced kidney cancer. About 30 adults with untreated advanced clear cell renal cell carcinoma will take part. The goal is to see if th…

This phase 1 trial tests a new drug called AWT020, given alone or with other cancer treatments, in people with advanced solid tumors such as non-small cell lung cancer, colorectal cancer, kidney cancer, and melanoma. The main goals are to check the drug's safety, find the best do…

This early-phase trial tests a new treatment for advanced kidney cancer that has spread. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The study will enroll 18 adults and focus on safety and finding the right dose, w…

This study tests whether adding targeted radiation or heat-based ablation to ongoing drug therapy can control genitourinary cancers (prostate, bladder, or kidney) that have started growing in only a few new areas. Participants continue their current systemic treatment while recei…

This study looks at whether taking vitamin B3 (a common dietary supplement) can stop antibiotics from weakening the immune system's ability to fight bladder cancer. The trial includes people with a certain type of bladder cancer who have recently taken antibiotics. They will rece…

This study tests a new drug called HRS-4508 in combination with other cancer treatments (such as capecitabine, trastuzumab, and pertuzumab) for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find the best dose, check safety, and…

This trial investigates whether ursodeoxycholic acid (UDCA), a bile acid medication, can protect kidney function in adults undergoing partial nephrectomy for kidney cancer. During surgery, blood flow to the kidney is temporarily stopped, which can cause injury. Participants take …

This early-phase trial is testing an experimental drug called BMS-986504 alongside standard cancer treatments in 60 people with advanced cancers that have lost a gene called MTAP. The cancers include mesothelioma, stomach/esophageal cancer, and bladder cancer. The main goal is to…

This Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…

This early-stage trial tests a new oral drug called SNV1521 in 400 people with advanced solid tumors that have spread. The main goals are to check safety, find the best dose, and see if it can shrink tumors. Researchers will also test SNV1521 combined with other cancer drugs.

This phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…

This early-stage trial tests a new drug called ONC-841 in people with advanced solid tumors that have spread. The drug is an antibody designed to help the immune system attack cancer cells. The study will first find a safe dose, then test it alone and with standard treatments for…

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …

This Phase II trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy (platinum and etoposide) before bladder removal surgery can completely eliminate the cancer in people with a rare, aggressive form of bladder cancer called small cell neuroe…

This trial tests a new type of immune cell therapy called bi-specific CAR-T cells that target two proteins (GD2 and PSMA) found on some solid tumors. The study involves 60 patients whose tumors have not responded to standard treatments. Researchers will check safety and whether t…

This early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…

This study tests a new treatment called 4SCAR-276 for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells that have a protein called CD276. The tria…

This early-phase trial is testing a new type of immune cell therapy called CLEAR CAR-T (ET-970) in 30 people with advanced clear cell kidney cancer that has not responded to at least two prior treatments. The therapy uses donor immune cells engineered to target a protein called C…

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This study tests whether the immunotherapy drug toripalimab can prevent kidney cancer from coming back in high-risk patients who have had their kidney removed. Researchers will also check if a blood test for minimal residual disease (MRD) can predict which patients benefit most. …

This early-phase trial is testing a new drug called H1710 in 36 adults with advanced solid tumors who have no standard treatment options left. The main goal is to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also watch for any …

This phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety …

This study tests whether a new combination of drugs (enfortumab vedotin plus toripalimab) works better than standard chemotherapy before bladder cancer surgery. About 58 adults with high-risk muscle-invasive bladder cancer will be randomly assigned to one of the two treatments fo…

This phase 1 trial tests a new therapy called MSK-TCR5 for people with advanced solid tumors that have a specific genetic change (RAS G12D mutation) and a certain immune type (HLA-A*11:01). The therapy uses a patient's own T-cells, modified in a lab to better recognize and attack…

This early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while als…

This early-stage study tests a new drug called STP938 in 70 adults with advanced solid tumors that cannot be cured by current treatments. The main goal is to check safety and find the right dose. The study also looks at how the drug moves through the body and includes a special g…

This study tests an experimental drug called YH32364 in adults with advanced solid tumors that have high levels of EGFR and have not responded to previous treatments. The trial has two parts: first, finding a safe dose in about 30 people, then testing that dose in 50 people with …

This study looks at the long-term safety and benefits of the drug pelabresib in people with blood cancers, solid tumors, or advanced cancers. It includes up to 50 adults who were in earlier pelabresib studies and are still benefiting from the drug. Some participants who received …

This early-stage trial tests a new drug called AN8025 in about 91 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Participants receive the drug in 3-week cycles and are closely moni…

This phase 2 trial tests a new radiation technique called SBRT-LATTICE-PATHY for people with large tumors (at least 7 cm or 340 cm³) that cannot be treated with standard methods. The approach delivers a high dose of radiation only to low-oxygen areas inside the tumor, aiming to i…

This study investigates whether combining the immunotherapy drug durvalumab with a cancer vaccine (S-488210/S-488211) can help people with a type of bladder cancer that has not responded to standard treatment. The trial includes adults with high-risk non-muscle invasive bladder c…

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This phase II trial is testing a combination of two drugs—disitamab vedotin given through a vein and mitomycin C placed directly into the bladder—in 30 people with a specific type of non-muscle-invasive bladder cancer that has a protein called HER2. The goal is to see if this tre…

This study tests a new treatment made from specially engineered immune cells (T cells) donated by healthy people. The cells are designed to better recognize and kill cancer cells while lasting longer in the body. The trial includes 24 adults with blood cancers or solid tumors tha…

This phase III trial tests whether adding local radiotherapy to standard care helps bladder cancer patients who are not eligible for curative treatment live longer and feel better. About 248 participants will be randomly assigned to receive either standard care alone or standard …

This study tests a new drug called IAH0968, given alone or with chemotherapy (CAPEOX), in people with advanced HER2-positive stomach cancer or other solid tumors. The goal is to see if the combination is safe and helps slow cancer growth better than standard treatment. About 574 …

This study tests a radioactive drug, 177Lu-PSMA-617, in people with advanced kidney cancer that has spread and worsened despite standard treatments like immunotherapy and targeted therapy. The drug targets a protein called PSMA found on kidney cancer cells, delivering radiation d…

This study is testing a non-invasive radiation treatment called SABR for people with kidney tumors who are not good candidates for surgery. The goal is to control the tumor while keeping the kidneys working well. About 90 participants will receive high-dose radiation and be follo…

This early-stage trial tests a new drug called MST-0312, designed to help the body's immune system fight cancer more effectively. It is being studied alone or with another cancer drug (pembrolizumab) in people with several types of solid tumors, including lung, melanoma, bladder,…

This early-stage trial is testing an experimental drug called HS-20108 in 502 people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. Researchers will also look for any signs that the drug might shr…

This early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…

This study tests a new drug called UI-102, which is a tiny nanoparticle designed to activate the immune system to fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments. The trial will enroll 140 participants to first find the saf…

This early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …

This study tests an experimental drug called RMC-9805, taken as a pill, in adults with advanced solid tumors (such as lung, colorectal, or pancreatic cancer) that have a specific mutation in the KRAS gene called G12D. The drug is given alone or in combination with another oral dr…

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This early-phase study tests a new drug called CT3001 in people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose of CT3001 alone, then testing it combined wit…

This early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…

This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…

This phase 2 trial tests whether the drug belzutifan can control metastatic clear cell renal cell carcinoma in people who are currently just being watched (active surveillance). Researchers will compare belzutifan to continued observation in 78 adults with slow-growing disease wh…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This early-phase study is testing a new treatment called KXV01 for people with advanced solid tumors, including sarcomas, who have no other options. The therapy uses a patient's own immune cells, modified with a virus to recognize and attack their specific tumor. The main goal is…

This early-phase trial tests AMT-676, a drug designed to seek out and destroy cancer cells that carry a protein called CDH17. It is given intravenously to 24 adults with advanced solid tumors (such as colorectal, gastric, or pancreatic cancer) that have not responded to prior tre…

This early-stage trial is testing whether it is safe to give immunotherapy (nivolumab) together with radiation therapy after bladder cancer surgery. The study will enroll 10 people who have had their bladder removed. The main goal is to see if this combination causes serious side…

This early-phase trial is testing a new drug called IUAb190708, an antibody designed to attack cancer cells by targeting a protein called PD-L1. The study involves 90 adults with advanced or recurrent solid tumors who have run out of standard treatment options. The main goal is t…

This early-phase study is testing a new drug called PEEL-224 in 65 people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look for signs that the drug can shrink tu…

This phase 2 trial is testing whether giving two drugs—toripalimab and lenvatinib—before and after surgery can improve outcomes for people with clear cell renal cell carcinoma. The study enrolls 75 patients with different stages of kidney cancer. Participants receive the drugs fo…

This early-stage trial tests whether injecting specially reprogrammed immune cell particles (exosomes) directly into tumors is safe for people with advanced solid tumors who have run out of standard options. Nine adults aged 18-65 will receive four injections over eight weeks. Th…

This study tests a new drug called SHR-9839, given with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination is safe and can shrink tumors. About 156 adults aged 18-75 with certain cancer…

This early-phase trial tests a new drug, UCB4594, in people with advanced solid tumors that haven't responded to standard treatments. The drug is a monoclonal antibody that targets a protein called HLA-G on cancer cells, potentially helping the immune system attack them. The stud…

This study tests a drug called romiplostim N01 in children, adolescents, and young adults (ages 6-24) with cancer who develop low platelet counts from chemotherapy. The drug is given as a weekly shot to help the body produce more platelets. The goal is to see if it can safely and…

This early-phase trial is testing a modified salmonella bacteria, called SGN1, in 70 people with advanced solid tumors that have not responded to standard treatments. The bacteria are designed to grow inside tumors and release an enzyme that breaks down methionine, an amino acid …

This study tests a modified herpesvirus (T3011) combined with standard immunotherapy drugs (PD-1/PD-L1 inhibitors) in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination is safe and can shrink tumors. About 68 parti…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This study compares 3 versus 6 cycles of platinum-based chemotherapy followed by the immunotherapy drug avelumab in 320 people with advanced bladder cancer. The goal is to see if fewer chemo cycles improve quality of life without harming cancer control. Participants receive eithe…

This study looks at whether removing the kidney tumor after starting immunotherapy helps people with advanced kidney cancer live longer. About 400 participants will be randomly assigned to have surgery or not. The goal is to see if delayed surgery improves overall survival compar…

This study tests a modified salmonella bacteria (SGN1) injected directly into tumors. The bacteria are designed to grow inside tumors and cut off their food supply (an amino acid called methionine), causing the tumors to shrink. The trial involves about 70 adults with advanced so…

This early-phase trial is testing a new treatment called NK521 for people with advanced solid tumors that have spread and caused fluid buildup in the belly (malignant ascites). The treatment uses a person's own natural killer (NK) cells that have been gene-edited to better attack…

This phase 2 trial tests whether combining two drugs—sacituzumab govitecan and nivolumab—after surgery can keep high-risk bladder cancer from coming back. About 23 adults who had their bladder or part of their urinary tract removed will receive the drugs intravenously. The main g…

This early-phase trial is testing whether a specially designed bacteria, CMTS1215, can safely shrink solid tumors. About 20 adults with advanced solid tumors who have no other treatment options will receive the bacteria directly into their tumor or through a vein. The main goals …

This early-phase study tests a new drug called AM-928, given as an IV infusion, in about 38 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and understand side effects. Researchers will also look for ear…

This study tests an experimental oral drug called NBM-BMX in people with advanced solid tumors or newly diagnosed glioblastoma (a type of brain cancer). The drug is given alone for solid tumors or combined with standard treatments (radiation and chemotherapy) for brain cancer. Th…

This study tests whether analyzing the genes of a kidney tumor can help doctors pick the best drug combination for each patient. Participants with advanced or metastatic clear cell kidney cancer will receive either two immunotherapy drugs (nivolumab plus ipilimumab) or one immuno…

This study is testing a precise type of radiation, called SBRT, for people with kidney cancer that cannot be removed with surgery. The treatment aims to control the tumor while limiting damage to healthy tissue. Researchers will track tumor control and quality of life in 70 parti…

This study tests an experimental therapy called GT201, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced solid tumors. About 18 adults will receive the treatment to see if it is safe and can shrink tumors. The goal is to control the disease, no…

This study tests a new oral drug called HEC169096 in people with advanced solid tumors, including thyroid cancer and non-small cell lung cancer, that have a specific RET gene change. The trial has two phases: the first finds the safest dose, and the second checks how well the dru…

This phase 2 trial tests a new radiation technique called lattice radiation therapy (LRT) combined with immunotherapy in 30 people with advanced solid tumors that have not responded to standard treatments. LRT delivers high doses of radiation to small spots inside the tumor while…

This early-phase trial tests a one-time infusion of specially engineered immune cells (CAR-NK cells) that target two proteins, CD70 and CAIX, found on kidney cancer cells. The study includes 36 adults with advanced clear cell renal cell carcinoma that has worsened after standard …

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This study tests a drug called toripalimab, which helps the immune system fight cancer, in people with advanced solid tumors that have specific genetic changes (POLE or POLD1 mutations) and have not responded to standard treatments. The trial aims to see if the drug can shrink tu…

This early-phase trial tests an experimental drug called GTB-5550 in adults with advanced solid tumors that have stopped responding to standard treatments. The drug is a nanobody designed to bridge natural killer cells to cancer cells, helping the immune system attack the tumor. …

This study looks at two ways to trigger ovulation in women with cancer who are freezing their eggs before chemotherapy. One method uses a GnRH agonist alone, the other combines it with hCG (dual trigger). The goal is to see which approach retrieves more eggs while reducing the ri…

This early-stage trial is testing a new drug called GS-2121, taken as a tablet, alone or with an intravenous drug called zimberelimab, in 154 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, …

This study tests whether combining a special PET scan (CAIX PET/CT) with standard therapy can better control advanced kidney cancer. About 70 adults with recurrent or metastatic clear cell renal cell carcinoma will receive targeted therapy and immunotherapy, plus precise radiatio…

This early-stage study tests a new drug called HDM2024 in 63 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check if the drug is safe and to see if it can shrink tumors. Participants receive the drug once every three weeks,…

This Phase 1 trial is testing an oral drug called AUR107 in 50 adults with advanced solid tumors that have come back after prior treatment. The study aims to find a safe dose and understand how the drug moves through the body. It is the first time AUR107 is being tested in humans…

This early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This study tests a new drug called XNW28012 in people with advanced solid tumors (pancreatic, ovarian, cervical, or colorectal cancers) that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug shri…

This early-stage trial is testing a new treatment called IB-T101 for people with advanced clear cell kidney cancer. The treatment uses a patient's own immune cells, called tumor-infiltrating lymphocytes, which are grown in a lab and then given back to the patient. The study will …

This early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three…

This phase IIa trial is testing two experimental drugs, HX009 and IN10018, given together with or without standard chemotherapy, in 124 adults with advanced solid tumors, specifically biliary tract cancer and melanoma. The study aims to find the best dose and see if the combinati…

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This early-stage trial tests a new drug called QXL138AM in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. The drug is designed to help the immune system attack cancer cells. The main goal is to check safety and find the…

This early-stage trial tests a genetically modified version of the Yersinia enterocolitica bacterium, given alone or with the immunotherapy pembrolizumab, in 100 adults with advanced solid tumors that have no standard treatment options. The goal is to find a safe dose and see if …

This early study tests a personalized mRNA vaccine (mRNA-0523-L001) for people with advanced endocrine tumors like adrenal cancer, medullary thyroid cancer, and pancreatic neuroendocrine tumors who have no standard treatment left. The vaccine is made to target unique mutations in…

This early-stage trial is testing an oral drug called HQP1351 in about 100 people with advanced gastrointestinal stromal tumors (GIST) or other solid tumors. The main goal is to find a safe dose and see how the body handles the drug. Participants take the pill every other day for…

This study tests a new treatment using donor immune cells (CAR-NK cells) that are engineered to recognize and attack cancer. The treatment is personalized based on a tumor's unique markers. It is for adults with advanced solid tumors that have not responded to other therapies. Th…

This early-phase trial is testing an experimental drug called DB-1310 in 1000 adults with advanced solid tumors that have worsened after standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. It is a first-in-human study, so the main…

This early-stage study is testing a new oral drug called CS23546 in about 156 adults with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Resear…

This early-phase study tests a new oral drug, TSL2109, in people with advanced solid tumors, especially prostate and breast cancers that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors o…

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …

This study tests a daily pill called olaparib in 20 adults with advanced kidney cancer that has spread. To join, your cancer must have a specific gene change (like BAP-1 or BRCA) and you must have already tried at least one other treatment. The goal is to see if olaparib can shri…

This study looks at whether a simple urine test for tumor DNA can tell which bladder cancer patients truly need a second surgery after their first tumor removal. About 196 adults with non-muscle-invasive bladder cancer will be randomly assigned to have their repeat surgery decisi…

This study collects video recordings and data from 500 patients undergoing blue light cystoscopy, a procedure where a drug makes cancer cells glow. The goal is to train an artificial intelligence (AI) algorithm to detect bladder lesions in real time, helping doctors make more acc…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This trial is testing whether a new PET imaging agent can safely and effectively detect a protein called MMP14 on solid tumors. The study will involve about 30 adults with various solid tumors, such as melanoma, lung, or breast cancer. Each participant will receive the experiment…

This study tests whether a specialized PET/CT scan using a radioactive tracer can more accurately determine the extent of muscle-invasive bladder cancer compared to standard CT scans. It will also explore whether changes seen on a follow-up scan after two cycles of chemotherapy c…

This study tests whether a simple urine test (Bladder EpiCheck) can safely replace some of the invasive cystoscopy procedures used to monitor non-muscle invasive bladder cancer. About 240 adults with low-grade intermediate-risk bladder cancer will be followed to compare quality o…

This study tests whether artificial intelligence can analyze MRI images to identify the type and aggressiveness of kidney tumors. Researchers will use scans from about 900 adults who have had surgery for kidney tumors, comparing AI predictions with the actual pathology results. T…

This study is testing whether a combined PET and MRI scan (PET/MR) can better tell apart aggressive kidney cancers from slow-growing or harmless tumors. About 97 adults with a suspicious kidney mass will receive the scan during their regular MRI appointment. Researchers hope this…

This study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …

This study is testing whether a protein called NMAP, measured in a blood sample, can help tell apart people with newly diagnosed kidney cancer from those without cancer. Researchers will compare NMAP levels in about 400 adults — half with kidney cancer and half without — to see h…

This phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain pr…

Urological diseases like kidney stones, prostate cancer, and bladder cancer are common but require expert diagnosis. This study will develop and test an AI assistant called UroAgent that helps doctors make decisions by analyzing patient records and images. Researchers will use 2,…

This early study tests whether a new radioactive tracer called 111In-XYIMSR-01 can help detect clear cell kidney cancer that has spread to other parts of the body. Six adults with confirmed metastatic clear cell renal cell carcinoma will receive the tracer and then undergo a SPEC…

This study tests if a very thin, single-use camera can be used in a doctor's office to look for cancer in the upper urinary tract, instead of doing it in an operating room under general anesthesia. Ten adults with known or suspected upper tract urothelial carcinoma will undergo t…

This study tests a new imaging agent called F18 FBPA, which is designed to light up cancer cells during a PET/CT scan. The agent targets a protein often found on solid tumors, potentially making tumors easier to see. Researchers want to find the best dose and timing for the scan,…

This study is testing whether a urine test can accurately detect urothelial carcinoma, a type of cancer that includes bladder cancer. Researchers are comparing the test results to standard tissue biopsies in 800 adults with blood in their urine and suspicious imaging findings. If…

This study is testing a new urine test called UroAmp to see if it can accurately detect bladder cancer and monitor for its return. Researchers will collect urine and tumor samples from 2,500 people being evaluated or treated for bladder cancer or related conditions. The goal is t…

This Phase II trial tests whether a special PET/CT scan using a radioactive tracer called 89Zr-DFO-girentuximab can find recurrent clear cell renal cell carcinoma after surgery better than standard contrast-enhanced CT. The tracer attaches to a protein (CAIX) on kidney cancer cel…

This study is testing a special MRI scan that uses a unique contrast agent to see how aggressive advanced solid tumors are and how they respond to treatment. About 65 people with advanced solid tumors will get the scan before and during their standard cancer therapy. The goal is …

This study tests a special PET/CT scan using a radioactive tracer called 68Ga-NYM096 to see if it can accurately detect clear cell kidney cancer in people with complex kidney cysts who are scheduled for surgery. About 70 participants will receive the tracer and undergo imaging be…

This study compares CT and MRI scans to see which more accurately determines if bladder cancer has spread into the muscle layer. About 150 adults with newly diagnosed bladder cancer will receive both scans before standard surgery. The results will be checked against tissue sample…

This study is testing a new blood test that looks for DNA from cancer cells. The goal is to see if an artificial intelligence program can accurately detect many different types of cancer at an early stage. The study will include 6,000 adults, some with cancer and some healthy vol…

This early-phase trial is testing a new radioactive imaging agent called 68Ga/18F-CAIX-LT-BCH to see if it can better detect clear cell renal cell carcinoma, a common type of kidney cancer. The study involves 3 participants who will receive the agent and undergo a PET/CT scan. Th…

This study is testing a new blood test that looks for DNA and protein signals from cancer cells. The goal is to find multiple types of cancer early, before they cause symptoms. Researchers will compare blood samples from 20,000 people with and without cancer to see if the test wo…

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This early-stage study tests a single dose of a new radioactive tracer called [68Ga]Ga-R54, which attaches to a protein (CXCR4) found on some cancer cells. Ten adults with advanced solid tumors or multiple myeloma will receive the tracer and then have a PET/CT scan to see where i…

This study tests a special PET/CT scan that uses radioactive tracers to find cancers that have a protein called CD70 on their surface. The cancers being studied include kidney cancer, lymphoma, and nasopharyngeal cancer. About 300 adults will receive an injection of the tracer an…

This study is testing a new, non-invasive urine test to detect clear cell renal cell carcinoma, a common type of kidney cancer. Currently, diagnosis often requires expensive imaging or a painful biopsy. Researchers are looking for tiny particles called exosomes in urine that are …

This study tests a new type of ultrasound called Super-Resolution Ultrasound Localization Microscopy to see if it can better detect bladder cancer before surgery. Thirty patients scheduled for bladder removal will receive this ultrasound while under anesthesia. The results will b…

This study is testing whether a special MRI scan (mpMRI) can accurately diagnose muscle-invasive bladder cancer without needing an invasive biopsy (TURBT). Researchers will compare the MRI results to the biopsy results in 30 adults with suspected muscle-invasive bladder cancer. I…

This study is testing whether regular urine tests every 6 months can find bladder cancer earlier in people at high risk, such as smokers over 50 and those with long-term workplace chemical exposure. Researchers will enroll 1,000 participants and track how many cancers are detecte…

This study is testing BCDx, a urine-based test designed to detect the return of non-muscle invasive bladder cancer (NMIBC) earlier and without a scope. Researchers will enroll 500 people with a history of NMIBC and compare the test's accuracy to standard cystoscopy. If it works, …

This early-stage trial is testing an injectable dye called NC527-X that may make tumors glow during surgery, helping surgeons see exactly where the cancer is. The study will enroll 400 adults with solid tumors who are already scheduled for surgery. Participants receive one of fou…

This study tests whether special MRI and CT scans can accurately measure the stiffness of kidney tumors. Researchers will compare these scans to standard methods in 50 adults scheduled for kidney tumor surgery. The goal is to improve 3D-printed models that help surgeons plan oper…

This study tests a new imaging probe called 89Zr-s-C1 that attaches to a protein (MUC18) found on some solid tumors. The goal is to see if this PET/CT scan can find tumors that standard scans miss. About 20 adults with newly diagnosed or recurring solid tumors (like melanoma or s…

This study is testing a new, non-invasive urine test that looks for a protein called CREPT in cells shed from the bladder. The goal is to see if this test can accurately detect bladder cancer and monitor if it comes back after treatment, potentially replacing uncomfortable and in…

This trial tests whether rinsing the bladder with sterile water during surgery works as well as a chemotherapy drug (gemcitabine) placed directly into the bladder to prevent cancer from coming back. People with upper tract urothelial carcinoma who are having surgery to remove the…

This study explores whether a brief behavioral program can help cancer patients and their sleep partners get better rest. The program teaches techniques like limiting time in bed and going to bed only when sleepy, aiming to improve sleep efficiency. Participants, who are couples …

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study tests whether psilocybin, the active ingredient in magic mushrooms, can help relieve severe pain in people with advanced cancer when opioids don't work. Fifteen participants will receive psilocybin capsules along with therapy sessions. The goal is to see if this approa…

This study tests whether adding Hydeal Cyst® instillations can reduce lower urinary tract symptoms in people receiving standard chemotherapy or immunotherapy for non-muscle invasive bladder cancer. About 200 participants will receive either BCG or MMC, and half will also get Hyde…

This study tests a navigation program for cancer patients starting immunotherapy. The program helps with essential needs like food, transportation, and housing, and tracks side effects. Researchers want to see if this support helps patients continue their treatment and improves t…

This trial tests whether Yunzhi essence, a mushroom extract from Coriolus versicolor, can improve quality of life for people with advanced cancer. Participants take either the extract or a placebo for six months, while researchers measure changes in well-being, survival, and immu…

This study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…

This study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …

This phase 2 trial tests whether a combination of olanzapine and ondansetron can prevent nausea and vomiting caused by high-dose cisplatin chemotherapy in people with solid tumors. The approach aims to reduce steroid use by omitting dexamethasone on days 2 through 4. The study en…

This study compares a combination of anesthesia methods (multimodal) to standard anesthesia for people having robotic kidney surgery for cancer. The goal is to see if the special approach helps patients recover more quickly, have less pain, and go home sooner. About 80 adults wil…

This study compares opioid-free anesthesia to standard opioid-based anesthesia in 600 adults undergoing urological abdominal surgery. The goal is to see if avoiding opioids during surgery reduces the need for painkillers afterward and lowers side effects like nausea. Patients wil…

This trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…

This study compares two ultrasound-guided nerve blocks for pain after open nephrectomy (kidney removal). 56 adults with kidney cancer will receive either an external oblique intercostal plane block or a posterior transversus abdominis plane block during surgery. The goal is to se…

This study tests whether a high-protein nutrition plan combined with resistance exercises, started weeks before surgery and continued for 24 weeks after, can help older adults with cancer preserve their physical function. The trial enrolls Veterans aged 55 and older with certain …

This pilot study tests whether brodalumab, a drug used for autoimmune conditions like psoriasis, can safely reduce immune-related side effects caused by cancer immunotherapy. About 11 adults with advanced solid tumors who developed these side effects will receive brodalumab injec…

This study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…

This study tests whether folic acid supplements can reduce mucositis (painful sores in the mouth, nose, throat, or other areas) in people with advanced kidney cancer who are on targeted therapy or immunotherapy. About 100 participants will receive either folic acid or a placebo, …

This study tests a special type of radiation called lattice therapy for people with large, hard-to-treat tumors. The goal is to see if it can shrink tumors better than standard radiation and help people feel better. About 37 adults with advanced solid tumors will receive this tre…

This study tests whether playing a serious game on an iPad can help older adults (60+) better manage nausea and vomiting caused by chemotherapy. About 610 participants will be randomly assigned to play the game or receive usual care. Researchers will track symptom severity, quali…

This study compares two approaches to supportive cancer care for nearly 3,000 adults with cancer. One group gets information through email or their health record, while the other works one-on-one with a lay health worker over 12 months. The goal is to see which model better impro…

This study looks at whether walking 8,000 to 10,000 steps each day for four weeks before bladder cancer removal surgery can lower the chance of problems after the operation. About 146 adults with bladder cancer who are scheduled for surgery will take part. Half will be asked to i…

This study looks at whether a one-day hospital visit that includes medical, psychological, and social support can help teens and young adults (ages 15-25) feel better after finishing cancer treatment. About 214 participants who have completed treatment for a solid tumor or lympho…

This study looks at whether medical hypnosis can help reduce anxiety in people with solid tumors who are getting radiation therapy. About 45 moderately to very anxious patients will either listen to relaxing music alone or combine it with hypnosis during their sessions. The goal …

This study is testing a precise form of radiation called proton beam therapy for children and young adults with kidney tumors like Wilms tumor. The goal is to see if this approach causes fewer short-term side effects compared to standard radiation. About 28 participants will rece…

This study looks at a rare inherited condition called Birt-Hogg-Dube (BHD) syndrome, which raises the risk of kidney cancer. Researchers will collect blood, saliva, and tissue samples from up to 950 participants to find the genes involved and understand how kidney tumors grow. Th…

This study tests a redesigned surgical tool for removing bladder tumors. Researchers will use the device on bladder specimens from 25 patients who need their bladder removed. The goal is to see if the modified device provides better tissue samples for pathology, helping doctors a…

This study monitors 202 adults in South Korea with advanced bladder cancer who are receiving the drug PADCEV (enfortumab vedotin) as part of their normal care. Researchers will track side effects and how well the cancer responds for up to a year. No new treatment is given; the go…

This study collects blood, urine, saliva, and tissue samples from nearly 6,000 people who have or may have cancer, including rare inherited forms. The samples are stored and used for research to understand the genetic and molecular basis of cancer. No new treatment is being teste…

This study tests whether a blood test that looks for tumor DNA can detect if bladder cancer has come back after treatment. Researchers will collect blood, urine, and tissue samples from 100 people with muscle-invasive bladder cancer to see how well the test matches standard metho…

This study is collecting blood, urine, and tumor tissue samples from about 400 adults with suspected high-risk non-muscle invasive bladder cancer. The goal is to find biological markers that could lead to new tests for detecting and monitoring this type of cancer. Participants wi…

This study follows families with a history of inherited kidney cancer to learn more about the disease's genetic causes and how it progresses. Researchers will collect blood, tissue, and urine samples from affected individuals and their relatives. The goal is to identify new genes…

This study looks at the best times to send messages that encourage physical activity to older cancer survivors (65+) who have chronic pain. About 50 participants will wear an activity tracker and rate their pain four times a day using a smartphone app. The goal is to see if certa…

This study is creating a decision aid called TA-DA to help people with advanced cancer talk with their doctors about whether to try more treatments after several have already failed. The tool is designed to support shared decision-making. Researchers will test it with 155 patient…

This early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal…

This study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study collects blood, urine, saliva, and tumor tissue from 500 adults with urothelial cancer (bladder, ureter, or urethra) and healthy volunteers. Researchers will analyze the samples to find genetic differences between normal and cancer cells. The goal is to better understa…

This early study will look at how two drugs, cabozantinib and nivolumab, change the bone immune environment in 16 people with kidney cancer that has spread to bone. The main goal is to check safety and see how the bone environment responds. It is a proof-of-concept study, meaning…

This study looks at how bladder cancer surgery affects quality of life and urinary function. Researchers will compare patients who had partial bladder removal with those who had full bladder removal. The goal is to understand which approach leads to better daily living and urinar…

This study is observing how bladder cancer is treated in Russia and how common certain markers (HER2 and PD-L1) are in different stages. Researchers will look at medical records of 600 people with bladder cancer to see what treatments they receive and how the disease progresses. …

This study is testing whether a blood test can find tiny pieces of tumor DNA in people with muscle-invasive bladder cancer or upper tract urothelial cancer. Researchers will compare DNA from tumor tissue with DNA in blood samples taken during routine care. The goal is to see how …

This study follows 1,100 adults with rare urinary tract cancers, such as unusual bladder, kidney, testicular, or penile cancers. Researchers will collect medical records, blood and tumor samples, and imaging over many years to understand how these cancers grow and respond to trea…

This study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…

This study analyzes data from over 6,000 French patients with non-metastatic kidney cancer to understand how the disease progresses after surgery. The goal is to identify which patients are at high risk of recurrence and might benefit from adjuvant immunotherapy, while avoiding u…

This study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …

This study collects tissue and blood samples from 1,500 people with prostate or bladder cancer that has come back or spread. Researchers will analyze the samples to find genetic changes and other markers that may explain why some cancers stop responding to treatment. The goal is …

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study aims to uncover the genetic causes of hereditary leiomyomatosis renal cell cancer (HLRCC), a condition that can lead to painful skin bumps, uterine fibroids, and kidney tumors. Researchers will study people with known or suspected HLRCC and their family members to iden…

This study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…

This global registry is collecting data on a surgical technique called en bloc resection of bladder tumour (ERBT), which removes the tumour in one piece rather than in fragments. The goal is to see whether this approach leads to complete tumour removal and better recurrence-free …

This study follows 300 men with upper tract urothelial cancer (UTUC), a rare cancer of the kidney's drainage system, to track their long-term survival, recurrence, and complication rates. By prospectively collecting data from patients before and after surgery or other interventio…

This study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…

This trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…

This study will enroll 200 adults aged 60 or older who are scheduled for major surgery for urologic cancer. Researchers want to see if an artificial intelligence analysis of a standard heart test (ECG) taken before surgery can predict whether a patient will suffer heart injury or…

This study tests two navigation systems—3D Slicer and Siemens Monaco—to help surgeons locate and remove abnormal lymph nodes during urologic cancer surgery. The goal is to see if these image-guided tools make the procedure simpler and more precise. Twenty adults with suspected or…

This study tests whether having a specialist review genetic test results and guide treatment decisions can increase the use of targeted therapies for people with advanced solid tumors, including breast, lung, colorectal, and bladder cancers. Participants will have their tumor or …

This study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…

This study follows 6,000 adults with solid tumors who are receiving immune checkpoint inhibitors as part of their routine cancer care. Researchers are tracking how long patients live and how long their disease stays under control. The goal is to learn how well these drugs work in…

This study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…

This study looks at how other medical conditions (comorbidities) affect recovery and survival in 500 bladder cancer patients after bladder removal surgery. Researchers will use artificial intelligence to analyze patient data and find patterns that could help doctors make better t…

This study compares spinal anesthesia to general anesthesia in men undergoing open simple prostatectomy for an enlarged prostate. The goal is to see if spinal anesthesia leads to less postoperative bleeding, such as fewer blood transfusions or less need for bladder irrigation. Ei…

This study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…

This study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…

This early-phase study tests a new radioactive tracer called [89Zr]DFO-starPEG to see if it can make tumors show up better on PET scans. The goal is to learn how the tracer behaves in the body and whether it can help doctors see the "leakiness" of tumor blood vessels, which may g…

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This pilot study is looking at whether levels of a common virus called TTV can help predict how well immunotherapy works in people with advanced kidney cancer. Researchers will measure TTV levels in 20 patients before and during their first immunotherapy treatment. The goal is to…

This study looks at whether certain bacteria or viruses in the bladder might be linked to bladder cancer. Researchers will compare the germs found in cancerous bladder tissue with those in healthy tissue from the same person. The goal is to see if there are differences that could…

This study is developing an AI system that tracks tumors and organs during radiation therapy without needing physical markers. Researchers will use existing patient data to train and test the AI. If it works, it could help doctors target radiation more accurately. The study invol…

This study is looking at whether tiny bits of tumor DNA (ctDNA) found in blood or urine can help doctors better understand and predict the course of a high-risk type of bladder cancer called T1G3. About 35 adults with this cancer will provide samples before, during, and after tre…

This study explores whether giving BCG therapy for non-muscle invasive bladder cancer at home is feasible and effective. It includes two groups: one to understand barriers to treatment compliance, and another to test a home BCG program with a chatbot that tracks symptoms and qual…

This study is for 150 adults having surgery for bladder cancer. Researchers want to see if the amount of fluid absorbed during surgery and changes in DNA in the blood can help predict if the cancer will return or get worse. The goal is to improve how doctors assess risk and plan …

This study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…

This study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…

This study aims to validate a gene test that identifies oxygen-starved (hypoxic) tumours in bladder and prostate cancer patients. About 30 participants will provide tumour samples and blood, and some will have MRI scans. The goal is to see if this test can help doctors choose mor…

This study enrolls 7,000 people with various cancers who have had or will have treatment aimed at a cure. Researchers collect blood, tissue, urine, and saliva samples over time to look for tiny bits of cancer DNA left behind. The goal is to find any remaining cancer as early as p…

This study is a registry that collects information from up to 1,000 people diagnosed with adrenocortical carcinoma, a rare cancer of the adrenal gland. The goal is to gather data on how the disease progresses and how different treatments work, so doctors can better understand the…

This study aims to learn more about how adrenal tumors form and to test new treatment options for adrenal cancer. Researchers will study up to 500 adults who have an adrenal tumor seen on imaging. The goal is to improve understanding and find better ways to treat these tumors.

This study looks at how immunotherapy drugs (anti-PD-1) affect bone strength in people being treated for cancer. Researchers will measure bone density and blood markers over a year in 25 patients. The goal is to understand if these treatments increase fracture risk, so doctors ca…

This study tracks drug levels in the blood of 200 people with advanced kidney cancer to see if monitoring can improve how well the drugs work and reduce side effects. Researchers will also look at how the body's immune system and genes affect treatment. The goal is to find better…

This study looks at how well different fluids (albumin and Ringer's solution) increase blood volume during laparoscopic surgery. About 60 adults having abdominal surgery will receive one of three fluid types. The goal is to see which fluid keeps the heart and blood vessels workin…

This study is a registry that collects information on how doctors treat and monitor patients with non-muscle-invasive bladder cancer in France. Researchers will track up to 8,000 adults to see how often cancer returns or worsens, and to test the accuracy of urine biomarker tests.…

This study is testing whether tiny particles in the blood, called extracellular vesicles, can predict nerve damage caused by chemotherapy. Researchers will follow 120 adults with various cancers who are receiving specific chemo drugs. Participants give blood samples and answer qu…

This study looks at two ways to help cancer patients preserve their fertility before treatments like chemotherapy. One group will freeze both ovarian tissue and eggs, while the other group will freeze only eggs. Researchers will compare how many eggs are retrieved in each group. …

This study looks at how certain drugs that affect the body's endocannabinoid system (similar to cannabis) change the way bladder muscle contracts. Researchers will take a small piece of healthy-looking bladder tissue from 65 adults having bladder cancer surgery. They will test th…

This study looks at 500 adults having cancer surgery to see which risk scoring system best predicts if they'll need intensive care afterward. Doctors will calculate scores like ASA and SORT from patient data before and during surgery. The goal is to find the most accurate tool to…

This study uses data from 4,700 kidney cancer patients treated at a single hospital over 12 years. The goal is to create a new model that better predicts how the disease will progress, especially for patients with a tumor thrombus. Researchers will also test whether using this mo…

This study tests whether using artificial intelligence (AI) to rewrite medical discharge letters into plain language helps cancer patients better understand their diagnosis, treatment, and next steps. About 150 adults with blood cancer or other cancers will be randomly assigned t…

This study enrolls up to 10,000 adults with cancer to see how a special team of experts (a molecular tumor board) uses genetic testing to recommend personalized treatments. Researchers will track whether doctors follow these recommendations and if patients benefit. The goal is to…

This study follows 50 adults with localized kidney cancer who have laparoscopic nephrectomy as an outpatient (no overnight stay). Researchers will record any complications that happen within the first month after surgery, such as pain, infection, or bleeding. The goal is to bette…